Akari Therapeutics, Plc (AKTX)

$ 1.4401
+0.01 (+0.71%)
Symbol AKTX
Price $ 1.4401
Beta 1.268
Volume Avg. 0.11M
Market Cap 0.075B
Shares () -
52 Week Range 1.32-4.21
1y Target Est -
DCF Unlevered AKTX DCF ->
DCF Levered AKTX LDCF ->
ROE -314.96% Strong Sell
ROA -322.28% Strong Sell
Operating Margin -
Debt / Equity 204.13% Strong Buy
P/E -
P/B 34.89 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest AKTX news

Dr. David Solomon
Nasdaq Capital Market

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.